Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L

Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma

(2022) Jingbo Qiao et al.   PLoS One

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

(2020) Álvaro Lahiguera et al.   EMBO Molecular Medicine

Endothelial cell CD36 optimizes tissue fatty acid uptake

(2018) Ni-Huiping Son et al.   JOURNAL OF CLINICAL INVESTIGATION

A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML

(2018) Samuel John et al.   MOLECULAR THERAPY

In vitro selection of RNA aptamers against CA125 tumor marker in ovarian cancer and its study by optical biosensing

(2016) Ilaria Lamberti et al.   METHODS

AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease

(2015) Lucía Sanjurjo et al.   JOURNAL OF LEUKOCYTE BIOLOGY

In vitro Selection and Interaction Studies of a DNA Aptamer Targeting Protein A

(2015) Regina Stoltenburg et al.   PLoS One

Myeloid-Specific Expression of Api6/AIM/Sp  Induces Systemic Inflammation and Adenocarcinoma in the Lung

(2014) P. Qu et al.   JOURNAL OF IMMUNOLOGY

Circulating AIM Prevents Hepatocellular Carcinoma through Complement Activation

(2014) Natsumi Maehara et al.   Cell Reports

A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis

(2013) Massimo Masiero et al.   CANCER CELL

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Macrophage-Derived AIM Is Endocytosed into Adipocytes and Decreases Lipid Droplets via Inhibition of Fatty Acid Synthase Activity

(2010) Jun Kurokawa et al.   Cell Metabolism

Tie2-mediated loss of peroxisome proliferator-activated receptor-γ in mice causes PDGF receptor-β-dependent pulmonary arterial muscularization

(2009) C. Guignabert et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior

(2009) R. L. Silverstein et al.   Science Signaling

Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy

(2008) L. M. Ellis et al.   CLINICAL CANCER RESEARCH

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies

(2008) Farbod Shojaei et al.   DRUG RESISTANCE UPDATES

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

(2008) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE